Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent kinase-4 gene

Cancer Research

Volumn 58, Issue 1, 1998, Pages 109-113

  Tsao, Hensin ^b   Benoit, Eric ^b   Sober, Arthur J ^b   Thiele, Carol ^c   Haluska, Frank G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIN DEPENDENT KINASE; CYSTEINE; GLUTAMINE; HISTIDINE; LYSINE; PROTEIN P16;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CODON; COLON CANCER; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MULTIPLE CANCER; NEUROBLASTOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UVEA MELANOMA;

BINDING SITES; CODON; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; EXONS; GERM-LINE MUTATION; HUMANS; MELANOMA; NEUROBLASTOMA; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED;

EID: 0031963952     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11, 136-140, 1995.
2. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
3. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330 1995.
4. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
5. Kamb, A., Gruis, N., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
6. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
7. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
8. Otsuki, T., Clark, H., Wellmann, A., Jaffe, E., and Raffeld, M. Involvement of CDKN2 (p16INK4A/MTS1) and p15ink4B/MTS2 in human leukemias and lymphomas. Cancer Res., 55: 1436-1440, 1995.
9. Cheng, J. Q., Jhanwar, S. C., Klein, W. M., Bell, D. W., Lee, W-C., Altonare, D. A., Nobori, T., Olopade, O. I., Buckler, A. J., and Testa, J. R. p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res., 54: 5547-5551, 1994.
10. Dreyling, M. H., Bohlander, S. K., Adeyanju, M. O., and Olopade, O. I. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interface fluorescence in situ hybridization. Cancer Res., 55: 984-988, 1995.
11. Caldas, C., Hahn, S., da Costa, L., Redston, M., Schutte, M., Seymour, A., Weinstein, C., Hruban, R., Yeo, C., and Kern, S. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
12. Otterson, G., Kratzke, R., Coxon, A., Kim, Y., and Kaye, F. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
13. Berner, J. M., Forus, A., Meltzer, P. S., Fodstad, O., and Mykelbost, O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer, 17: 254-259, 1996.
14. He, J., Allen, J. R., Collins, V. P., Allalunis-Turner, M. J., Godbout, R., Day, R. S. R., and James, C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54: 5804-5807, 1994.
15. Sonoda, Y., Yoshimoto, T., and Sekiya, T. Homozygous deletion of the MTS1/p16 and MTS/p15 genes and amplification of the CDK4 gene in glioma. Oncogene, 11: 2145-2149, 1995.
16. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
17. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
18. INK4a binding domain of CDK4 in familial melanoma. Nat. Genet., 12: 97-99, 1996.
19. FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., Sober, A. J., and Haber, D. A. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA, 93: 8541-8545, 1996.
20. Hayward, N., Flores, J., Pollock, P., Walker, G., Glendening, J. M., Lin, A., Palmer, J., Walters, M., and Fountain, J. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Melanoma Res., 7: S37, 1997.
21. Platz, A., Hansson, J., Mansson-Brahme, E., Lundqvist, E., Sevigny, P., Inganas, M., Walles, W., and Ringborg, U. Population based screening of germline mutations in the CDKN2A, CDKN2B, CDK4 and p53 genes in Swedish families with hereditary cutaneous melanoma. Melanoma Res., 7: S37, 1997.
22. Holland, E. A., Becker, T. A., Kefford, R. F., and Mann, G. J. Mutation analysis of CDKN2A and CDK4 in familial melanoma. Melanoma Res., 7: S133, 1997.
23. Piccinin, S., Doglioni, C., Maestro, R., Vukosavljevic, T., Gasparotto, D., D'Orazi, C., and Boiocchi, M. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. Cancer, 74: 26-30, 1997.
24. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A. F., Zeuthen, J., and Bartek, J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56: 5475-5483, 1996.
25. Bressac-de Paillerets, B., Soufir, N., Chompret, A., Bombled, J., Demenais, F., Spatz, A., and Avril, M. F. Germ-line mutations in p16 and CDK4 in 38 melanoma families. Melanoma Res., 7: S132, 1997.
26. Otterson, G. A., Kratzke, R. A., Coxon, A., Whan, Y. W., and Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
27. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal RB Inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
28. Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M., and Brodeur, G. M. No CDKN2 mutations in neuroblastomas. Cancer Res., 55: 2053-2055, 1995.
29. Fountain, J. W., Karayiorgou, M., Ernstoff, M. S., Kirkwood, J. M., Vlock, D. R., Titus-Ernstoff, L., Bouchard, B., Vijayasaradhi, S., Houghton, A. N., Lahti, J., Kidd, V. J., Housman, D. E., and Dracopoli, N. C. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. USA, 89: 10557-10561, 1992.
30. Ohta, M., Berd, D., Shimizu, M., Hirokazu, N., Cotticelli, M-G., Mastrangelo, M., Shields, J. A., Shields, C. L., Croce, C. M., and Huebner, K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int. J. Cancer, 65: 762-767, 1996.
31. Thiele, C. J., McKeon, C., Triche, T. J., Ross, R. A., Reynolds, C. P., and Israel, M. A. Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system. J. Clin. Invest., 80: 804-811, 1987.
32. Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., Barnhill, R. L., Hayward, N. K., Housman, D. E., and Fountain, J. W. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers in sporadic melanoma. Cancer Res., 56: 5023-5032, 1996.
33. Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., and Ponten, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 88: 10124-10128, 1991.
34. Elwood, J. M. Melanoma and sun exposure. Semin. Oncol., 23: 650-666, 1996.
35. Coleman, K. G., Wautlet, B. S., Morrissey, D., Mulheron, J., Sedman, S. A., Brinkley, P., Price, S., and Webster, K. R. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J. Biol. Chem., 272: 18869-18874, 1997.
36. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
37. Matsouka, S., Edwards, M., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J., and Elledge, S. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
38. Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N., and Winoto, A. Identification of human and mouse p19, novel CDK4 and CDK6 inhibitor with homology to P16ink4. Mol. Cell. Biol., 15: 2682-2688, 1995.